Viral Vector Delivery of ENPP1 and ENPP3 Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases involving ENPP1 or ENPP3 deficiencies, such as generalized arterial calcification of infants, lack effective methods to provide functional ENPP1 or ENPP3 proteins to mammals, leading to inadequate inhibition of ectopic tissue mineralization and calcification.
Innovation Solution
The use of recombinant polynucleotides encoding ENPP1 or ENPP3, delivered via viral vectors like Adeno-Associated Viral Vectors, to express functional ENPP1 or ENPP3 proteins in mammals, thereby inhibiting ectopic calcification by increasing pyrophosphate levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used for ENPP1 or ENPP3 deficiencies, then the disease condition remains untreated, but no effective method exists to provide functional proteins
Solution Approach 1:
The patent uses viral vectors as intermediary carriers to deliver recombinant polynucleotides encoding ENPP1 or ENPP3 proteins into mammalian cells. The viral vector acts as a mediator that bridges the gap between the therapeutic gene and the target cells, enabling effective protein delivery where none previously existed. This resolves the contradiction by providing both the functional protein (improving reliability) and a delivery mechanism (improving ease of manufacture/availability).
Solution Approach 2:
The recombinant polynucleotide sequences are designed to be self-expressing within the host organism. Once delivered via the viral vector, the polynucleotides autonomously direct the synthesis of functional ENPP1 or ENPP3 proteins in the mammalian cells, eliminating the need for continuous external administration of the protein itself. This self-service capability ensures sustained therapeutic effect while simplifying the treatment regimen.
2Object-affected harmful factors
If pyrophosphate levels are increased to inhibit ectopic calcification, then mineralization is reduced, but the mechanism requires effective protein delivery which currently lacks
Solution Approach 1:
The therapeutic approach is segmented into distinct functional components: (1) the recombinant polynucleotide sequence encoding the desired protein, (2) the viral vector delivery system, and (3) the endogenous protein expression machinery within host cells. This segmentation allows each component to be optimized independently - the polynucleotide for maximal protein expression, the viral vector for efficient delivery, and leverages the host's existing cellular machinery to produce the pyrophosphate-increasing effect, thereby reducing overall system complexity.
Solution Approach 2:
The patent changes the fundamental parameter of protein delivery from exogenous protein administration to endogenous protein expression via gene delivery. This parameter change transforms the therapeutic mechanism from directly administering the protein (complex stability, dosage control issues) to delivering the genetic instructions for protein synthesis, which the host cells then translate into functional ENPP1 or ENPP3 proteins that naturally regulate pyrophosphate levels and inhibit ectopic calcification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The expression of ENPP1 or ENPP3 proteins through viral vectors effectively reduces ectopic calcification and mineralization, providing a therapeutic approach to treat conditions like generalized arterial calcification of infants by enhancing pyrophosphate levels.
Implementation Method 1
ENPP1 (also known as PC-1) is a type 2 extracellular membrane-bound glycoprotein located on the mineral-depositing matrix vesicles of osteoblasts and chondrocytes and hydrolyzes extracellular nucleotides (principally ATP) into adenosine monophosphate (AMP) and inorganic pyrophosphate (PPi)
Implementation Method 2
ENPP3 like ENPP1 also belongs to the phosphodiesterase I/nucleotide pyrophosphatase enzyme family. These enzymes are type II transmembrane proteins that catalyze the cleavage of phosphodiester and phosphosulfate bonds of a variety of molecules, including deoxynucleotides, NAD, and nucleotide sugars
Implementation Method 3
The use of recombinant polynucleotides encoding ENPP1 or ENPP3, delivered via viral vectors like Adeno-Associated Viral Vectors, to express functional ENPP1 or ENPP3 proteins in mammals
Data Source
AI summary
The present disclosure provides, among other things, vectors for expression of ENPP1 or ENPP3 in vivo and methods for the treatment of diseases of calcification and ossification in a subject.